Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should?

Affiliations

¹ Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, Colorado. Electronic address: Gregory.Schwartz@va.gov.
² Center for Comprehensive Cardiovascular Care, St. Louis University School of Medicine, St. Louis, Missouri.

Free article

Editorial

Gregory G Schwartz et al. J Am Coll Cardiol. 2019.

Free article

. 2019 Nov 19;74(20):2463-2465.

doi: 10.1016/j.jacc.2019.09.039.

¹ Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, Colorado. Electronic address: Gregory.Schwartz@va.gov.
² Center for Comprehensive Cardiovascular Care, St. Louis University School of Medicine, St. Louis, Missouri.

No abstract available

Keywords: LDL-C; PCSK9 inhibitor; acute coronary syndrome; ezetimibe; statin.

Comment on

Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Koskinas KC, et al. J Am Coll Cardiol. 2019 Nov 19;74(20):2452-2462. doi: 10.1016/j.jacc.2019.08.010. Epub 2019 Aug 31. J Am Coll Cardiol. 2019. PMID: 31479722 Clinical Trial.